Targeting APBs offers a promising therapeutic strategy for ALT-positive cancers. Disrupting the formation or function of APBs could inhibit the ALT pathway, leading to telomere shortening and subsequent [cell death](#). Researchers are exploring various approaches, including small molecules and siRNA, to specifically target components of APBs and disrupt their function.